The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension
Open accessAbstract
In an elegant example of bench to bedside research, a hypothesis that cells in the outflow pathway actively regulate conventional outflow resistance was proposed in the 1990s and systematically pursued, exposing novel cellular and molecular mechanisms of IOP regulation. The critical discovery that pharmacological manipulation of the cytoskeleton of outflow pathway cells decreased outflow resistance placed a spotlight on the Rho kinase pathway that was known to regulate the cytoskeleton. Ultimately, a search for Rho kinase inhibitors led to the discovery of several molecules of therapeutic interest, leaving us today with two new ocular hypotensive agents approved for clinical use – ripasudil in Japan and netarsudil in the US. These represent members of the first new class of clinically useful ocular hypotensive agents since the US FDA approval of latanoprost in 1996. The development of Rho kinase inhibitors as a class of medications to lower intraocular pressure in patients with glaucoma and ocular hypertension represents a triumph in translational research. Rho kinase inhibitors are effective alone or when combined with other known ocular hypotensive medications. They also offer the possibility of neuroprotective activity, a favorable impact on ocular blood flow and even an anti-fibrotic effect that may prove useful in conventional glaucoma surgery. Local adverse effects, however, including conjunctival hyperemia, subconjunctival hemorrhages and cornea verticillata, are common. Development of Rho kinase inhibitors targeted to the cells of the outflow pathway and the retina may allow these agents to have even greater clinical impact. The objectives of this review are to describe the basic science underlying the development of Rho kinase inhibitors as a therapy to lower intraocular pressure and to summarize the results of the clinical studies reported to date. The neuroprotective and vasoactive properties of Rho kinase inhibitors as well as the antifibrotic properties of these agents are reviewed in the context of their possible role in the medical and surgical treatment of glaucoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pathophysiology and Treatment of Glaucoma: A Review
Weinreb, R. N., Aung, T., & Medeiros, F. A. (2014) · JAMA · doi:10.1001/jama.2014.3192 · Cited by 4,210
Kass, M. A. (2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.6.701 · Cited by 3,705
Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors
Takemoto, M., & Liao, J. K. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq1101.098486 · Cited by 1,272
Lichter, P. (2001) · Ophthalmology · doi:10.1016/s0161-6420(01)00873-9 · Cited by 1,178
Rho‐kinase/ROCK: A key regulator of the cytoskeleton and cell polarity
Amano, M., Nakayama, M., & Kaibuchi, K. (2010) · Cytoskeleton · doi:10.1002/cm.20472 · Cited by 994
Rho Signaling Pathway Targeted to Promote Spinal Cord Repair
Dergham, P., Ellezam, B., Essagian, C., Avedissian, H., Lubell, W. D., & McKerracher, L. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-15-06570.2002 · Cited by 726
Wound healing in glaucoma filtering surgery
Skuta, G. L., & Parrish, R. K. (1987) · Survey of Ophthalmology · doi:10.1016/0039-6257(87)90091-9 · Cited by 630
Rho kinase, a promising drug target for neurological disorders
Mueller, B. K., Mack, H., & Teusch, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1719 · Cited by 608
‘What controls aqueous humour outflow resistance?’
Johnson, M. (2006) · Experimental Eye Research · doi:10.1016/j.exer.2005.10.011 · Cited by 482
Self-citationRho and Ras GTPases in axon growth, guidance, and branching
Hall, A., & Lalli, G. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001818 · Cited by 437
Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632.
Rao, P., Pf, D., Kumar, J., & Dl, E. (2001) · PubMed · Cited by 422
Honjo, M., Tanihara, H., Inatani, M., Kido, N., Sawamura, T., Yue, B. Y., Narumiya, S., & Honda, Y. (2001) · PubMed · Cited by 385
Uveoscleral drainage of aqueous humour in human eyes
Bill, A., & Phillips, C. I. (1971) · Experimental Eye Research · doi:10.1016/0014-4835(71)90149-7 · Cited by 347
Cofilin phosphatases and regulation of actin dynamics
Huang, T. Y., DerMardirossian, C., & Bokoch, G. M. (2006) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.11.005 · Cited by 339
Rho‐associated kinases in tumorigenesis: re‐considering ROCK inhibition for cancer therapy
Rath, N., & Olson, M. F. (2012) · EMBO reports · doi:10.1038/embor.2012.127 · Cited by 302
Serle, J. B., Katz, L. J., McLaurin, E., Heah, T., Ramirez-Davis, N., Usner, D. W., Novack, G. D., & Kopczynski, C. C. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.11.019 · Cited by 269
Overby, D. R., Stamer, W. D., & Johnson, M. (2009) · Experimental Eye Research · doi:10.1016/j.exer.2008.11.033 · Cited by 263
Self-citationOcular perfusion pressure in glaucoma
Costa, V. P., Harris, A., Anderson, D., Stodtmeister, R., Cremasco, F., Kergoat, H., Lovasik, J., Stalmans, I., Zeitz, O., Lanzl, I., et al. (2014) · Acta Ophthalmologica · doi:10.1111/aos.12298 · Cited by 255
Ripasudil: First Global Approval
Garnock-Jones, K. P. (2014) · Drugs · doi:10.1007/s40265-014-0333-2 · Cited by 242
Cytoskeletal involvement in the regulation of aqueous humor outflow.
Tian, B., Geiger, B., Epstein, D. L., & Kaufman, P. L. P. (2000) · PubMed · Cited by 239
McCullough, B. R., Blanchoin, L., Martiel, J.-L., & De La Cruz, E. M. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.05.055 · Cited by 235
Bill, A., & Svedbergh, B. (1972) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.1972.tb05954.x · Cited by 223
Unconventional aqueous humor outflow: A review
Johnson, M., McLaren, J. W., & Overby, D. R. (2017) · Experimental Eye Research · doi:10.1016/j.exer.2016.01.017 · Cited by 221
Self-citationBösel, J., Gandor, F., Harms, C., Synowitz, M., Harms, U., Djoufack, P. C., Megow, D., Dirnagl, U., Hörtnagl, H., Fink, K. B., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02980.x · Cited by 210
Novel Insights into the Roles of Rho Kinase in Cancer
Wei, L., Surma, M., Shi, S., Lambert-Cheatham, N., & Shi, J. (2016) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-015-0382-6 · Cited by 205
Dysfunctional regulation of ocular blood flow: A risk factor for glaucoma?
Harris, A. (2008) · Clinical Ophthalmology · doi:10.2147/opth.s2774 · Cited by 201
ROCK2 is a major regulator of axonal degeneration, neuronal death and axonal regeneration in the CNS
Koch, J. C., Tönges, L., Barski, E., Michel, U., Bähr, M., & Lingor, P. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.191 · Cited by 197
Rho Kinases in Health and Disease: From Basic Science to Translational Research
Loirand, G. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010595 · Cited by 194
Tanihara, H., Inoue, T., Yamamoto, T., Kuwayama, Y., Abe, H., & Araie, M. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.05.016 · Cited by 190
Altered mechanobiology of Schlemm’s canal endothelial cells in glaucoma
Overby, D. R., Zhou, E. H., Vargas-Pinto, R., Pedrigi, R. M., Fuchshofer, R., Braakman, S. T., Gupta, R., Perkumas, K. M., Sherwood, J. M., Vahabikashi, A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410602111 · Cited by 188
Self-citationLin, C.-W., Sherman, B., Moore, L. A., Laethem, C. L., Lu, D.-W., Pattabiraman, P. P., Rao, P. V., deLong, M. A., & Kopczynski, C. C. (2018) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2017.0023 · Cited by 187
Rho GTPase/Rho Kinase Inhibition as a Novel Target for the Treatment of Glaucoma
Rao, V. P., & Epstein, D. L. (2007) · BioDrugs · doi:10.2165/00063030-200721030-00004 · Cited by 184
Tokushige, H., Inatani, M., Nemoto, S., Sakaki, H., Katayama, K., Uehata, M., & Tanihara, H. (2007) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.05-1617 · Cited by 177
Biomechanics of Schlemm's canal endothelium and intraocular pressure reduction
Stamer, W. D., Braakman, S. T., Zhou, E. H., Ethier, C. R., Fredberg, J. J., Overby, D. R., & Johnson, M. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.08.002 · Cited by 177
Self-citationToris, C. B., Camras, C. B., & Yablonski, M. E. (1999) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(99)00076-8 · Cited by 164
Tanihara, H. (2008) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2007.76 · Cited by 163
Rho-associated kinase inhibitors: A novel glaucoma therapy
Inoue, T., & Tanihara, H. (2013) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2013.05.002 · Cited by 162
Zhou, Q., Gensch, C., & Liao, J. K. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.12.006 · Cited by 160
Netarsudil Increases Outflow Facility in Human Eyes Through Multiple Mechanisms
Ren, R., Li, G., Le, T. D., Kopczynski, C., Stamer, W. D., & Gong, H. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-20189 · Cited by 158
Modulation of outflow resistance by the pores of the inner wall endothelium.
Johnson, M., Shapiro, A. H., Ethier, C. R., & Kamm, R. D. (1992) · PubMed · Cited by 156
Self-citationYamamoto, K. T., Maruyama, K., Himori, N., Omodaka, K., Yokoyama, Y., Shiga, Y., Morin, R., & Nakazawa, T. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-13842 · Cited by 155
Bacharach, J., Dubiner, H. B., Levy, B. L., Kopczynski, C., & Novack, G. D. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.08.022 · Cited by 155
Tanihara, H., Inoue, T., Yamamoto, T., Kuwayama, Y., Abe, H., Suganami, H., & Araie, M. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2015.0525 · Cited by 146
Rao, P. V., Deng, P., Sasaki, Y., & Epstein, D. L. (2004) · Experimental Eye Research · doi:10.1016/j.exer.2004.08.029 · Cited by 146
Statins inhibit Rho kinase activity in patients with atherosclerosis
Nohria, A., Pršić, A., Liu, P., Okamoto, R., Creager, M. A., Selwyn, A. P., Liao, J. K., & Ganz, P. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.12.023 · Cited by 143
Potential Role of Rho-Associated Protein Kinase Inhibitor Y-27632 in Glaucoma Filtration Surgery
Honjo, M., Tanihara, H., Kameda, T., Kawaji, T., Yoshimura, N., & Araie, M. (2007) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-0878 · Cited by 142
Rho GTPases as regulators of mitosis and cytokinesis in mammalian cells
Chircop, M. (2014) · Small GTPases · doi:10.4161/sgtp.29770 · Cited by 140
Tanihara, H., Inoue, T., Yamamoto, T., Kuwayama, Y., Abe, H., Fukushima, A., Suganami, H., & Araie, M. (2015) · Acta Ophthalmologica · doi:10.1111/aos.12829 · Cited by 137
McKerracher, L. J., & Winton, M. J. (2002) · Neuron · doi:10.1016/s0896-6273(02)01018-8 · Cited by 136
Williams, R. D., Novack, G. D., van Haarlem, T., & Kopczynski, C. (2011) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.04.012 · Cited by 131
An emerging treatment option for glaucoma: Rho kinase inhibitors
Chang, R. T., & Wang, S. K. (2014) · Clinical ophthalmology · doi:10.2147/opth.s41000 · Cited by 125
Sherwood, M. B. (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.9.1230 · Cited by 125
Meyer‐ter‐Vehn, T., Sieprath, S., Katzenberger, B., Gebhardt, S., Grehn, F. J., & Schlunck, G. ̈. (2006) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.06-0118 · Cited by 121
Phase 1 Clinical Trials of a Selective Rho Kinase Inhibitor, K-115
Tanihara, H. (2013) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.323 · Cited by 118
The Development of Topical Carbonic Anhydrase Inhibitors
Maren, T. H. (1995) · Journal of Glaucoma · doi:10.1097/00061198-199502000-00012 · Cited by 117
Honjo, M., Inatani, M., Kido, N., Sawamura, T., Yue, B. Y., Honda, Y., & Tanihara, H. (2001) · Archives of Ophthalmology · doi:10.1001/archopht.119.8.1171 · Cited by 114
Myosin light chain kinase activation and calcium sensitization in smooth muscle in vivo
Mizuno, Y., Isotani, E., Huang, J., Ding, H., Stull, J. T., & Kamm, K. E. (2008) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.90645.2007 · Cited by 113
Effect of AR-13324 on Episcleral Venous Pressure in Dutch Belted Rabbits
Kiel, J. W., & Kopczynski, C. (2015) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2014.0146 · Cited by 112
Autoregulation and neurovascular coupling in the optic nerve head
Prada, D., Harris, A., Guidoboni, G., Siesky, B. A., Huang, A. M., & Arciero, J. C. (2015) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2015.10.004 · Cited by 108
Zhou, E. H., Krishnan, R., Stamer, W. D., Perkumas, K. M., Rajendran, K., Nabhan, J. F., Lu, Q., Fredberg, J. J., & Johnson, M. (2011) · Journal of The Royal Society Interface · doi:10.1098/rsif.2011.0733 · Cited by 108
Self-citationDiscovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma
Sturdivant, J. M., Royalty, S. M., Lin, C., Moore, L. A., Yingling, J. D., Laethem, C. L., Sherman, B. W., Heintzelman, G. R., Kopczynski, C., & deLong, M. A. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.03.104 · Cited by 108
Systemic Vascular Dysregulation and Retrobulbar Hemodynamics in Normal-Tension Glaucoma
Galassi, F., Giambene, B., & Varriale, R. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-6710 · Cited by 104
Cordeiro, M. F., Reichel, M. B., Gay, J. A., D'Esposita, F., Alexander, R., & Khaw, P. T. (1999) · PubMed · Cited by 103
Lewis, R. A., Levy, B. L., Ramirez, N., Kopczynski, C., Usner, D. W., Novack, G. D., & for the PG324-CS201 Study Group (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-306778 · Cited by 100
Latrunculin-A increases outflow facility in the monkey.
Peterson, J. A., Tian, B., Bershadsky, A. D., Volberg, T., Gangnon, R. E., Spector, I., Geiger, B., & Kaufman, P. L. P. (1999) · PubMed · Cited by 94
de Velde, S. V., Bergen, T. V., Sijnave, D., Hollanders, K., Castermans, K., Defert, O., Leysen, D. C., Vandewalle, E., Moons, L., & Stalmans, I. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-13157 · Cited by 92
Rho/Rho-associated kinase pathway in glaucoma
WANG, J., Liu, X., & Zhong, Y. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2100 · Cited by 89
Effects of Cholesterol-Lowering Statins on the Aqueous Humor Outflow Pathway
Song, J., Deng, P., Stinnett, S. S., Epstein, D. L., & Rao, P. V. (2005) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.04-0776 · Cited by 88
Strzelecka‐Kiliszek, A., Mebarek, S., Roszkowska, M., Buchet, R., Magne, D., & Pikuła, S. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.02.005 · Cited by 86
Effects of Latrunculin-B on Outflow Facility and Trabecular Meshwork Structure in Human Eyes
Ethier, C. R., Read, A. T., & Chan, D. W.-H. (2006) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.05-0327 · Cited by 81
Glaucomatous Optic Neuropathy Associated with Nocturnal Dip in Blood Pressure
Melgarejo, J. D., Lee, J. H., Petitto, M., Yépez, J. B., Murati, F. A., Jin, Z., Chávez, C. A., Pirela, R. V., Calmón, G. E., Lee, W., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.11.029 · Cited by 80
Self-citationLiu, J., Gao, H., & Wang, X. (2015) · Neural Regeneration Research · doi:10.4103/1673-5374.170325 · Cited by 79
de Velde, S. V., Groef, L. D., Stalmans, I., Moons, L., & Hove, I. V. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.06.002 · Cited by 78
Effect of Latrunculin-B on Outflow Facility in Monkeys
Peterson, J. A., Tian, B., Geiger, B., & Kaufman, P. L. (2000) · Experimental Eye Research · doi:10.1006/exer.1999.0797 · Cited by 78
SAGAWA, H., Terasaki, H., Nakamura, M., Ichikawa, M., Yata, T., TOKITA, Y., & WATANABE, M. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.02.002 · Cited by 78
Hensel, N., Rademacher, S., & Claus, P. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00198 · Cited by 76
Sugiyama, T., Shibata, M., Kajiura, S., Okuno, T., Tonari, M., Oku, H., & Ikeda, T. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-5265 · Cited by 76
Shaw, P. X., Sang, A., Wang, Y., Ho, D., Douglas, C. R., Dia, L., & Goldberg, J. L. (2016) · Experimental Eye Research · doi:10.1016/j.exer.2016.07.006 · Cited by 70
Divergent Roles of Nitric Oxide and Rho Kinase in Vasomotor Regulation of Human Retinal Arterioles
Hein, T. W., Rosa, R. H., Yuan, Z., Roberts, E., & Kuo, L. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-4391 · Cited by 69
Tokushige, H., Waki, M., Takayama, Y., & Tanihara, H. (2011) · Current Eye Research · doi:10.3109/02713683.2011.599106 · Cited by 67
Elevated Levels of RhoA in the Optic Nerve Head of Human Eyes With Glaucoma
Goldhagen, B. E., Proia, A. D., Epstein, D. L., & Rao, P. V. (2012) · Journal of Glaucoma · doi:10.1097/ijg.0b013e318241b83c · Cited by 63
Circadian Variation of Aqueous Humor Dynamics in Older Healthy Adults
Nau, C. B., Malihi, M., McLaren, J. W., Hodge, D. O., & Sit, A. J. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-12690 · Cited by 61
Principles and practice of ophthalmology
Lai, J. (2000) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(00)00595-x · Cited by 61
Whitlock, N. A., Harrison, B. A., Mixon, T., Yu, X.-Q., Wilson, A., Gerhardt, B., Eberhart, D. E., Abuin, A., & Rice, D. S. (2009) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2008.0142 · Cited by 39
Sato, S., Hirooka, K., Nitta, E., Ukegawa, K., & Tsujikawa, A. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0389-3 · Cited by 36
Townes‐Anderson, E., Wang, J., Halász, É., Sugino, I. K., Pitler, A., Whitehead, I. P., & Zarbin, M. A. (2017) · Translational Vision Science & Technology · doi:10.1167/tvst.6.3.22 · Cited by 34
RhoA/Rho Kinase Mediates Neuronal Death Through Regulating cPLA2 Activation
Wu, X., Walker, C. L., Lu, Q., Wu, W., Eddelman, D. B., Parish, J. M., & Xu, X. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0187-6 · Cited by 33
Kopczynski, C., Novack, G. D., Swearingen, D., & van Haarlem, T. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2012-302466 · Cited by 30
Grewe, R. (1986) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/s-2008-1050606 · Cited by 24
Skaat, A., Jasien, J. V., & Ritch, R. H. (2016) · Journal of Glaucoma · doi:10.1097/ijg.0000000000000508 · Cited by 23
Cited by
Rho GTPase signaling in cancer progression and dissemination
Crosas-Molist, E., Samain, R., Kohlhammer, L., Orgaz, J. L., George, S. L., Maiques, O., Barcelo, J., & Sanz-Moreno, V. (2022) · Physiological Reviews · doi:10.1152/physrev.00045.2020 · Cited by 272
The concept of gene therapy for glaucoma: the dream that has not come true yet
Sulak, R., Liu, X., & Smedowski, A. (2024) · Neural Regeneration Research · doi:10.4103/1673-5374.375319 · Cited by 40
“RhoA kinase inhibitors are currently used as topical treatments for glaucoma and ocular hypertension (e.g., netarsudil, ripasudil) (Tanna and Johnson, 2018).”
BackgroundStack, T., Vincent, M., Vahabikashi, A., Li, G., Perkumas, K. M., Stamer, W. D., Johnson, M., & Scott, E. (2020) · Small · doi:10.1002/smll.202004205 · Cited by 37
Self-citationLi, H., Henty-Ridilla, J. L., Bernstein, A. M., Ganapathy, P. S., & Herberg, S. (2022) · Current Eye Research · doi:10.1080/02713683.2022.2071943 · Cited by 29
Metadata
- Authors
- Tanna, A. P., & Johnson, M.
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2018-11
- Volume
- 125
- Issue
- 11
- Pages
- 1741-1756
- ISSN
- 0161-6420 (ISSN-L)
- OpenAlex
- W2884952526
- Cited by
- 257
- References
- 90
- FWCI
- 22.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.